Hematology/Oncology Clinics of North America
Volume 21, Issue 2 , Pages 303-319, April 2007

Bevacizumab for Advanced Breast Cancer

  • Tiffany A. Traina, MD

      Affiliations

    • Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Hope S. Rugo, MD

      Affiliations

    • Breast Oncology Clinical Trials Program, University of California, San Francisco Comprehensive Cancer Center, 2356 Sutter Street, 6th Floor, Box 1710, San Francisco, CA 94143, USA
    • ,
  • Maura Dickler, MD

      Affiliations

    • Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA

Tumor angiogenesis is essential for the growth and metastasis of solid tumors. In breast cancer, increased levels of vascular endothelial growth factor (VEGF) have been associated with poor prognosis in lymph node–positive and lymph node–negative patients. In addition to its prognostic significance, VEGF is now a validated target in the treatment of breast cancer. Bevacizumab, an anti-VEGF antibody, has demonstrated significant clinical benefit in several solid tumors. In this article the authors discuss the data pertaining to bevacizumab and other antiangiogenic agents for the treatment of patients who have advanced breast cancer.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0889-8588(07)00020-2

doi:10.1016/j.hoc.2007.03.006

Hematology/Oncology Clinics of North America
Volume 21, Issue 2 , Pages 303-319, April 2007

Article Tools

* Image Usage & Resolution